| Ytd | -95.58% | |
| 1y | -99.80% |
| Open | 0.85 | Prev Close | 0.86 | Low | 0.77 | High | 0.86 | Mkt Cap | 2.69M |
| Vol | 194.70K | Avg Vol | 767.46K | EPS | -57.79 | P/E | N/A | Forward P/E | N/A |
| Beta | -1.51 | Short Ratio | 1.88 | Inst. Own | 16.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.62 | 200-d Avg | 10.68 | 1yr Est | 0.00 |
CMND News
VANCOUVER, BC September 17, 2026 - TheNewswire — StickIt Technologies Inc. (CSE: STKT) (the "Company
Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine, spoke on patient access and sh
Vancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “C
Clearmind Medicine Inc. (NASDAQ:CMND) (the "Company" or "Clearmind"), a clinical-sta
Vancouver, Canada, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “C
Gainers iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market
Gainers Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular se
Shares of Clearmind Medicine Inc. (NASDAQ:CMND) are trading lower Friday morning as investors digest
Clearmind Medicine shares are trading lower Friday as investors weigh the biotech’s move to acquire
Charging Robotics is one of the few worldwide developing innovative wireless charging systems desig
Clearmind Medicine Inc. (NASDAQ:CMND) (the "Company"), a clinical-stage biopharmaceutical co
Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “C
SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that its sub
Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biopharmaceutical company advancing non-h
U.S. publication of the patent application covering the MDMA-N-acylethanolamines combination expands
U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands i
The independent Data and Safety Monitoring Board on Thursday unanimously approved Clearmind Medicine
Clearmind Medicine advances the CMND-100 clinical trial for alcohol use disorder to Parts B and C fo
Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to adva
Vancouver, Canada, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY
Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to adva
Vancouver, Canada, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearm
Completed treatment as planned per-protocol, reinforcing the strength of its proprietary drug candid
Vancouver, Canada, July 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clini
All 24 participants across cohorts 1 through 4 have successfully completed treatment according to th
Vancouver, Canada, July 28, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (“Clearmind” or “Compan
The Hong Kong patent application forms part of Clearmind’s exclusive worldwide licensing agreement w
Vancouver, Canada, July 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ("Clearmind") (Nasdaq:
Vancouver, Canada, July 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clini
Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potent
Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clini
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta
Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage a biotech company developing novel, non-hall
The program is evaluating intranasal delivery of MEAI as a potential additional route of administrat
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta
Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announce
This advancement strengthens Clearmind's robust intellectual property portfolio, which already
The approval advances the multicenter study titled "A Phase I/II Single and Multiple Dose Tolera
US stocks down, Nasdaq drops 200 points. Dow -0.35% at 49,512.48, Nasdaq -0.93% at 25,849.08, S&